CA3261035A1 - Pharmaceutical composition comprising kras g12d inhibitor - Google Patents
Pharmaceutical composition comprising kras g12d inhibitorInfo
- Publication number
- CA3261035A1 CA3261035A1 CA3261035A CA3261035A CA3261035A1 CA 3261035 A1 CA3261035 A1 CA 3261035A1 CA 3261035 A CA3261035 A CA 3261035A CA 3261035 A CA3261035 A CA 3261035A CA 3261035 A1 CA3261035 A1 CA 3261035A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- ammonium
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Claims (16)
- 37 CLAIMS 1. A pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and a lipid, .
- 2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a liposome.
- 3. The pharmaceutical composition according to claim 1 or 2, wherein the lipid comprises at least one phospholipid, and the phospholipid is preferably dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3- phosphatidylcholine (PLPC), dioleoylphosphatidylcholine (DOPC), dierucoylphosphatidylcholine (DEPC), egg yolk phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), hydrogenated soy phosphatidylcholine (HSPC), 1- myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2- myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), palmitoyloleoylphosphatidylcholine (POPC), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, distearoylphosphatidylethanolamine (DSPE), dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylglycerol (DOPG), dimyristoylphosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dipalmitoylglycerophosphoglycerol (DPPG), dipalmitoylphosphatidylserine (DPPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylserine (DOPS), dimyristoylphosphatidylserine (DMPS), distearoylphosphatidylserine (DSPS), dipalmitoylphosphatidic acid (DPPA), 1,2-dioleoyl-sn-glycero-3-phosphatidic acid (DOPA), dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dipalmitoylphosphatidylinositol (DPPI), 1,2-dioleoyl-sn-glycero-3-phosphatidylinositol (DOPI), dimyristoylphosphatidylinositol (DMPI), distearoylphosphatidylinositol (DSPI), and derivatives thereof; more preferably dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC),38 dierucoylphosphatidylcholine (DEPC), dilauroylphosphatidylcholine (DLPC), hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylethanolamine (DSPE), and dimyristoylphosphatidylcholine (DMPC), and polyethylene glycol-modified derivatives thereof; most preferably hydrogenated soy phosphatidylcholine (HSPC) and polyethylene glycol 2000-distearoylphosphatidylethanolamine (mPEG2000-DSPE).
- 4. The pharmaceutical composition according to any one of claims 1-3, wherein the phospholipid has a molar percentage selected from the group consisting of 10%-80%, preferably 30%-70%, relative to a total amount of a lipid mixture.
- 5. The pharmaceutical composition according to any one of claims 1-4, wherein the lipid further comprises a steroid, preferably cholesterol.
- 6. The pharmaceutical composition according to claim 5, wherein the steroid has a molar percentage selected from the group consisting of 0.1%-90%, preferably 10%-80%, and more preferably 20%-70%, relative to the total amount of the lipid mixture.
- 7. The pharmaceutical composition according to any one of claims 1-6, further comprising a trapping agent, wherein the trapping agent is preferably a sulfate, a sulfite, a gluconate, a phosphate, a hydrogen phosphate, a molybdate, a carbonate, and a nitrate, and is more preferably ammonium sulfate, ammonium phosphate, ammonium molybdate, ammonium sucrose octasulfate, triethylammonium sucrose octasulfate, copper gluconate, ethylammonium sulfate, ammonium ethylenediaminetetraacetate, ammonium chloride, ammonium hydroxide, ammonium acetate, dextran ammonium sulfate, or triethyldextran ammonium sulfate, and combinations thereof.
- 8. The pharmaceutical composition according to any one of claims 1-7, wherein an inner aqueous phase of the liposome further comprises at least one pH adjuster, and the pH adjuster is preferably sodium hydroxide, hydrochloric acid, ammonia water, phosphoric acid, malic acid, histidine, or triethanolamine.
- 9. The pharmaceutical composition according to any one of claims 1-8, wherein the compound of formula I or the pharmaceutically acceptable salt thereof has a concentration selected from the group consisting of 0.01-100 mg/mL, preferably 0.05-10 mg/mL.
- 10. The pharmaceutical composition according to any one of claims 1-9, wherein an outer aqueous phase of the liposome comprises one or more selected from the group consisting of a sugar, an electrolyte, and an amino acid or a salt thereof, preferably sodium chloride and histidine or a salt thereof.39
- 11. A lyophilized composition, wherein the lyophilized composition is obtained by lyophilizing or spray-drying the pharmaceutical composition according to any one of claims 1-10.
- 12. A lyophilized composition, wherein the lyophilized composition is capable of being reconstituted to give the pharmaceutical composition according to any one of claims 1-10.
- 13. A reconstituted solution, wherein the reconstituted solution is obtained by reconstituting the lyophilized composition according to claim 11.
- 14. A liposome, comprising a compound of formula I or a pharmaceutically acceptable salt thereof, .
- 15. A method for preparing the pharmaceutical composition according to any one of claims 2-10 or the liposome according to claim 14, comprising steps of preparing a blank liposome, and introducing the compound of formula I or the pharmaceutically acceptable salt thereof into an inner aqueous phase of the blank liposome.
- 16. Use of the pharmaceutical composition according to any one of claims 1-10, the lyophilized composition according to claim 11 or 12 or the reconstituted solution according to claim 13 or the liposome according to claim 14 in the preparation of a medicament for treating a disease or disorder, wherein the disease or disorder is preferably a cancer, and is more preferably selected from the group consisting of brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, laryngeal cancer, oral cancer, salivary gland cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer, renal cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, colorectal cancer, small intestine cancer, gastrointestinal stromal tumor, urothelial cancer, urinary tract cancer, bladder cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma,40 skin cancer, lipoma, bone cancer, soft tissue sarcoma, neurofibroma, neuroglioma, neuroblastoma, and glioblastoma.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210909959 | 2022-07-29 | ||
| CN202210909959.1 | 2022-07-29 | ||
| CN202211642769 | 2022-12-20 | ||
| CN202211642769.4 | 2022-12-20 | ||
| PCT/CN2023/109901 WO2024022507A1 (en) | 2022-07-29 | 2023-07-28 | Pharmaceutical composition comprising kras g12d inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3261035A1 true CA3261035A1 (en) | 2025-04-04 |
Family
ID=89705462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3261035A Pending CA3261035A1 (en) | 2022-07-29 | 2023-07-28 | Pharmaceutical composition comprising kras g12d inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4563151A4 (en) |
| JP (1) | JP2025524799A (en) |
| KR (1) | KR20250037564A (en) |
| CN (1) | CN119384279A (en) |
| AU (1) | AU2023314335A1 (en) |
| CA (1) | CA3261035A1 (en) |
| MX (1) | MX2025001036A (en) |
| TW (1) | TW202408536A (en) |
| WO (1) | WO2024022507A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202315626A (en) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | Pyrimidine-fused cyclic compound and preparation method and use thereof |
| CN119365467A (en) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | Aza-tetracyclic oxazapine compounds and uses thereof |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN121487738A (en) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | Compositions for inducing RAS GTP hydrolysis and their uses |
| KR20260019479A (en) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Combination therapy for RAS-related diseases or disorders |
| CN121889155A (en) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | RMC-6291 for the treatment of RAS protein-related diseases or disorders |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968570B2 (en) * | 2013-01-14 | 2018-05-15 | Chemo-Enhanced Llc | Compositions and methods for treating cancer |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN114615981B (en) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | KRAS G12D inhibitors |
| CN112745335B (en) * | 2019-10-30 | 2024-08-30 | 武汉誉祥医药科技有限公司 | Tri-heterocyclic compound and application thereof |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2021203768A1 (en) * | 2020-04-08 | 2021-10-14 | 江苏恒瑞医药股份有限公司 | Pyrimido dicyclo derivative, preparation method therefor and use thereof in medicine |
| WO2022017339A1 (en) * | 2020-07-20 | 2022-01-27 | 江苏恒瑞医药股份有限公司 | Fused pyridazine derivative, preparation method therefor and pharmaceutical use thereof |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (en) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | Pyrimidinocyclic compounds and their preparation methods and uses |
| MX2023015533A (en) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Fused tetracyclic compound, preparation method therefor and application thereof in medicine. |
| CN117677624A (en) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | Novel Pyridopyrimidine Derivatives |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
-
2023
- 2023-07-28 KR KR1020257005566A patent/KR20250037564A/en active Pending
- 2023-07-28 CN CN202380046186.1A patent/CN119384279A/en active Pending
- 2023-07-28 EP EP23845711.3A patent/EP4563151A4/en active Pending
- 2023-07-28 TW TW112128471A patent/TW202408536A/en unknown
- 2023-07-28 WO PCT/CN2023/109901 patent/WO2024022507A1/en not_active Ceased
- 2023-07-28 CA CA3261035A patent/CA3261035A1/en active Pending
- 2023-07-28 AU AU2023314335A patent/AU2023314335A1/en active Pending
- 2023-07-28 JP JP2025501568A patent/JP2025524799A/en active Pending
-
2025
- 2025-01-24 MX MX2025001036A patent/MX2025001036A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023314335A1 (en) | 2025-02-27 |
| EP4563151A4 (en) | 2025-11-05 |
| KR20250037564A (en) | 2025-03-17 |
| TW202408536A (en) | 2024-03-01 |
| CN119384279A (en) | 2025-01-28 |
| EP4563151A1 (en) | 2025-06-04 |
| JP2025524799A (en) | 2025-08-01 |
| WO2024022507A1 (en) | 2024-02-01 |
| MX2025001036A (en) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5981214B2 (en) | Compositions and methods for the treatment of lymphoma | |
| JP4874547B2 (en) | Drug loading method to liposome by gradient | |
| US20040228909A1 (en) | Compositions and methods for treating lymphoma | |
| US12059499B2 (en) | Liposome loading | |
| US20040071768A1 (en) | Compositions and methods for treating cancer | |
| AU2023314335A1 (en) | Pharmaceutical composition comprising kras g12d inhibitor | |
| IL278079B1 (en) | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | |
| EP2968146B1 (en) | Controlled drug release liposome composition | |
| CA2184834A1 (en) | Liposome preparation | |
| WO2014047116A1 (en) | Encapsulating liposomes | |
| JP4950890B2 (en) | Delivery of iron to animals | |
| RU2025103683A (en) | PHARMACEUTICAL COMPOSITION CONTAINING KRAS G12D INHIBITOR | |
| US7244450B2 (en) | Compositions and methods for treating lymphoma | |
| CA3032687C (en) | Liposomal composition containing mild acidic active agent | |
| WO2021239134A1 (en) | Liposome containing ethylenediamine tetraacetic acid or salt thereof and eribulin or pharmaceutically acceptable salt thereof | |
| WO2025235614A1 (en) | Liposome loading with polyanions | |
| RU2021132189A (en) | PHARMACEUTICAL COMPOSITION OF A WEAK ACID DRUG AND METHODS OF APPLICATION | |
| HK1125833A (en) | Compositions and methods for treating lymphoma | |
| HK1255538B (en) | Liposome loading | |
| HK1160032B (en) | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab | |
| HK1160032A (en) | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241231 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241231 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250404 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250404 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250404 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250404 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250610 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250610 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260528 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260602 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260603 |